Brokerages predict that Ascendis Pharma A/S (NASDAQ:ASND) will post ($1.18) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Ascendis Pharma A/S’s earnings. The highest EPS estimate is ($1.02) and the lowest is ($1.31). Ascendis Pharma A/S reported earnings of ($1.08) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 9.3%. The business is expected to report its next earnings results on Wednesday, March 27th.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full-year earnings of ($3.90) per share for the current financial year, with EPS estimates ranging from ($4.13) to ($3.28). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.56) per share, with EPS estimates ranging from ($5.50) to ($0.44). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, November 28th. The biotechnology company reported ($0.94) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.23) by $0.29. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.16 million.
Several equities research analysts have recently issued reports on ASND shares. BidaskClub upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Tuesday, December 18th. Zacks Investment Research upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $82.00 price target for the company in a report on Friday, January 18th. Wedbush set a $81.00 price target on Ascendis Pharma A/S and gave the company a “buy” rating in a report on Friday, January 25th. Finally, Credit Suisse Group lifted their price target on Ascendis Pharma A/S from $80.00 to $86.00 and gave the company an “outperform” rating in a report on Thursday, November 29th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $85.89.
Several institutional investors have recently made changes to their positions in the company. Quantamental Technologies LLC bought a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $25,000. Lindbrook Capital LLC bought a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $54,000. SG Americas Securities LLC bought a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $116,000. Virtus ETF Advisers LLC bought a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $300,000. Finally, PNC Financial Services Group Inc. raised its stake in shares of Ascendis Pharma A/S by 28.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,760 shares of the biotechnology company’s stock valued at $480,000 after acquiring an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 95.67% of the company’s stock.
Shares of Ascendis Pharma A/S stock traded up $0.16 during trading on Monday, hitting $68.55. 130,580 shares of the stock traded hands, compared to its average volume of 226,280. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of -15.83 and a beta of 0.92. Ascendis Pharma A/S has a twelve month low of $48.72 and a twelve month high of $76.99.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Featured Story: What is Cost of Debt?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.